Pertuzumab as personalized therapy for breast cancer - Video abstract 37100
Video abstract of review paper "Precision medicine and personalized breast cancer: combination pertuzumab therapy" published in the open access journal Pharmacogenomics and Personalized Medicine by Reynolds et al.
Abstract: Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody, binds to a different domain of HER2 and prevents the formation of HER2:HER3 dimers, which is the most potent heterodimer in the HER family.
Read this review and sign up to receive Pharmacogenomics and Personalized Medicine journal here: http://www.dovepress.com/precision-medicine-and-personalized-breast-cancer-combination-pertuzum-peer-reviewed-article
Show speech transcript
